AMGEN Inc

NASDAQ: AMGN
$295.42
+$0.89 (+0.3%)
Real Time Data Delayed 15 Min.

AMGN Articles

The January 31 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The top analyst upgrades, downgrades and other research calls from Monday include Amgen, Boeing, Chevron, Exxon Mobil, Foot Locker, Lowe's, Nokia, PayPal, Sprint and Wells Fargo.
The top analyst upgrades, downgrades and other research calls from Friday include Alibaba, Alphabet, Amazon, Amgen, Apple, Mastercard, Nokia, Shopify and US Steel.
The January 12 short interest data have been compared with the previous report, and short interest moves in the selected biotech stocks were mixed.
The top analyst upgrades, downgrades and other research calls from Tuesday include Amgen, Caterpillar, Dollar General, Duke Energy, General Electric, Honeywell, 3M, Netflix and Sprint.
Apple indicated that it will pay $38 billion in repatriation taxes under the new tax law. Apple says that it is already the largest U.S. taxpayer and that a payment of that size likely would be the...
The December 29 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Merrill Lynch believes that this could be the year biotechs break out. The firm has a few picks, bad and good, that it believes will play a big role in the coming year.
There can be some big biotech winners in 2018, given the changing landscape, and any of these 12 could be one.
The December 15 short interest data have been compared with the previous report, and short interest in the selected biotech stocks increased.
The November 30 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
One industry that could be a huge winner from tax reform, and may surprise some investors, is biotechnology, especially for the large cap leaders in the group.
It is no secret that biotech stocks can bring great rewards for investors. They can also deliver serious pain. Fortunately, most of these are currently projected to deliver a solid 2018.
The October 31 short interest data have been compared with the previous report, and short interest in the selected biotech stocks was mixed.
Merrill Lynch points to five companies that, in their words, should be key players in the young but growing biosimilar market.